

Medicinal product no longer authorised

Annex IV

Conclusions on the granting of the conditional marketing authorisation and presented by the European Medicines Agency

Conclusions presented by the European Medicines Agency on:

- **Conditional marketing authorisation**

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.

Medicinal product no longer authorised